Linezolid is indicated for the treatment of adults (12 years and older) and pediatric patients (birth through 11 years of age) with the following infections caused by the susceptible strains of the designated Gram-positive bacteria only. Linezolid is not indicated for the treatment of Gram-negative infections. Speciﬁc Gram-negative therapy is required if a concomitant Gram- negative pathogen is documented or suspected (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Community-acquired pneumonia caused by Streptococcus pneumoniae (penicillin-sensitive strain only), including cases with concurrent bacteraemia, or Staphylococcus aureus (methicillin-sensitive strain only).
Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-sensitive and methicillin-resistant strains) or Streptococcus pneumoniae (penicillin-sensitive strains only).
Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-sensitive strains only) or Streptococcus pyogenes.
Complicated skin and skin structure infections, caused by Staphylococcus aureus (methicillin-sensitive and methicillin resistant strains), Streptococcus pyogenes or Streptococcus agalactiae.
Vancomycin-resistant Enterococcus faecium including cases with concurrent bacteraemia.
Linezolid should not be initiated as a ﬁrst line therapy for community acquired pneumonia or uncomplicated skin infection, but may be considered if resistant strains are suspected or proven or in presence of drug allergy.